Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis

Hongmei Li, Patricia Gonnella, Farinaz Safavi, Ghazal Vessal, Bardia Nourbakhsh, Fang Zhou, Guang Xian Zhang, Abdolmohamad Rostami

Research output: Contribution to journalArticlepeer-review

Abstract

Zymosan has previously been reported to have both pro-inflammatory and anti-inflammatory effects. Here we demonstrate that low dose zymosan prevented or reversed chronic and relapsing paralysis in EAE. In suppressing CNS autoimmune inflammation, zymosan not only regulated APC costimulator and MHC class II expression, but also promoted differentiation of regulatory T cells. Following adoptive transfer of zymosan-primed CD4+ T cells, recipient mice were protected from EAE. In contrast, a MAPK inhibitor and a blocker of β-glucan, reversed the effects of zymosan. These results demonstrate that zymosan may be a promising beneficial agent for Multiple Sclerosis (MS).

Original languageEnglish (US)
Pages (from-to)28-38
Number of pages11
JournalJournal of Neuroimmunology
Volume254
Issue number1-2
DOIs
StatePublished - Jan 15 2013

Keywords

  • CD11cCD11b DCs
  • EAE/MS
  • Macrophage/microglia
  • Treg
  • Zymosan

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis'. Together they form a unique fingerprint.

Cite this